Bexarotene

• CAT Number: A001128
• CAS Number: 153559-49-0
• Molecular Formula: C24H28O2
• Molecular Weight: 348.5
• Purity: ≥95%
• Synonyms: LGD1069; Targretin
• Target: Retinoid X Receptors
• Solubility: >10.4mg/mL in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
• InChI: InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)
• InChIKey: NAVMQTYZDKMPEU-UHFFFAOYSA-N
• SMILES: CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C

Bexarotene (CAS 153559-49-0), also known as LGD-1069, is a synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties. Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression.

Overview of Clinical Research

Bexarotene is a peroxisome proliferator-activated receptor agonist, a protein synthesis inhibitor and a retinoid X receptor agonist developed by Ligand Pharmaceuticals. 

Reference

1:Successful Treatment of Primary Cutaneous Peripheral T-Cell Lymphoma Presenting Acquired Ichthyosis with Oral Bexarotene Monotherapy. Tanita K, Fujimura T, Sato Y, Hidaka T, Furudate S, Kambayashi Y, Tsukada A, Hashimoto A, Aiba S.Case Rep Oncol. 2017 Apr 6;10(1):328-332. doi: 10.1159/000468981. eCollection 2017 Jan-Apr. PMID: 28512419 Free PMC Article
2:The long non-coding RNA Neat1 is an important mediator of the therapeutic effect of bexarotene on traumatic brain injury in mice. Zhong J, Jiang L, Huang Z, Zhang H, Cheng C, Liu H, He J, Wu J, Darwazeh R, Wu Y, Sun X.Brain Behav Immun. 2017 May 5. pii: S0889-1591(17)30145-9. doi: 10.1016/j.bbi.2017.05.001. [Epub ahead of print] PMID: 28483659
3:Late-onset bexarotene-induced CD4 lymphopenia in a cutaneous T-cell lymphoma patient. Eshagh K, Romero LS, So JK, Zhao XF.Cutis. 2017 Feb;99(2):E30-E34. PMID: 28319634
4:Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma. Cabello I, Servitje O, Corbella X, Bardés I, Pintó X.Clin Exp Dermatol. 2017 Apr;42(3):276-281. doi: 10.1111/ced.13044. Epub 2017 Feb 24. PMID: 28233333
5:DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators. Heitel P, Achenbach J, Moser D, Proschak E, Merk D.Bioorg Med Chem Lett. 2017 Mar 1;27(5):1193-1198. doi: 10.1016/j.bmcl.2017.01.066. Epub 2017 Jan 25. PMID: 28169169
6:Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma. Duvic M, Kim YH, Zinzani PL, Horwitz SM.Clin Cancer Res. 2017 Feb 6. doi: 10.1158/1078-0432.CCR-16-2064. [Epub ahead of print] PMID: 28167509
7:Nanoformulation of dual bexarotene-tailed phospholipid conjugate with high drug loading. He R, Du Y, Ling L, Ismail M, Hou Y, Yao C, Li X.Eur J Pharm Sci. 2017 Mar 30;100:197-204. doi: 10.1016/j.ejps.2017.01.012. Epub 2017 Jan 12. PMID: 28088372
8:Mycosis Fungoides of the Oral Cavity: Fungating Tumor Successfully Treated with Electron Beam Radiation and Maintenance Bexarotene. Bassuner J, Miranda RN, Emge DA, DiCicco BA, Lewis DJ, Duvic M.Case Rep Dermatol Med. 2016;2016:5857935. doi: 10.1155/2016/5857935. Epub 2016 Dec 15. PMID: 28074163 Free PMC Article
9:Triggering of Suicidal Erythrocyte Death by Bexarotene. Al Mamun Bhuyan A, Bissinger R, Cao H, Lang F.Cell Physiol Biochem. 2016;40(5):1239-1251. Epub 2016 Dec 15. PMID: 27978526 Free Article
10:Simple and sensitive HPLC-UV method for determination of bexarotene in rat plasma. Lee JB, Zgair A, Kim TH, Kim MG, Yoo SD, Fischer PM, Gershkovich P.J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jan 1;1040:73-80. doi: 10.1016/j.jchromb.2016.11.024. Epub 2016 Nov 17. PMID: 27978471